Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14046896 | 0.94 | BRPF1 (0.51) | BRPF1POLBMAPTKDM4ETP53 | |
| SCHEMBL11948998 | 0.90 | HDAC6 (0.48) | BRPF1POLBMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL11949054 | 0.90 | BRPF1 (0.48) | BRPF1POLBMAPTKDM4ETP53 | |
| SCHEMBL11949046 | 0.89 | ALOX15 (0.48) | BRPF1MAPTHDAC6PARP1ABL1 | |
| SCHEMBL11948989 | 0.89 | ABL1 (0.47) | BRPF1HDAC6PARP1ABL1HSD17B10 | |
| SCHEMBL11957169 | 0.88 | HDAC6 (0.48) | BRPF1NPC1RAB9AHDAC6ABL1 | |
| SCHEMBL3106553 | 0.88 | HDAC6 (0.48) | BRPF1MAPTTP53NPC1PKM | |
| SCHEMBL11949059 | 0.88 | HDAC6 (0.51) | BRPF1POLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL11949045 | 0.88 | BRPF1 (0.55) | BRPF1POLBMAPTKDM4ETP53 | |
| SCHEMBL11949058 | 0.87 | HDAC6 (0.50) | BRPF1HDAC6ABL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013142326-A1 | 5-CARBONYLAMINO-/(SULFONAMIDO-) SUBSTITUTED BENZ IMIDAZOLES AND USE THEREOF TREATMENT OF TUBERCULOSIS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2013-09-26 | — | — | WO | disclosed |
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TBCD, TBC1D5, CFTR | BRPF1 266/4885POLB 2717/4885MAPT 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.